Roche Receives Approval for Laboratory Based Elecsys SARS-CoV-2 Antigen Test to Facilitate High-Volume Testing in the Country
| Tuesday | 8th June, 2021
The laboratory based Elecsys SARS-CoV-2 Antigen test had earlier received CE mark has recently obtained the import license from CDSCO.
Roche’s Elecsys SARS-CoV-2 Antigen test is an immunoassay intended for the qualitative detection of SARS-CoV-2 present in the respiratory tract including nasopharynx and oropharynx.
The Elecsys SARS-CoV-2 Antigen test is performed by healthcare professionals and could be used as an alternative or in conjunction with PCR testing.
In symptomatic individuals, a positive result with the Elecsys SARS-CoV-2 Antigen test indicates an active SARS-CoV-2 infection with a likelihood of 94.5%.
Detection of acute infections (SARS-CoV-2 PCR or Antigen) Detection of immune response(SARS-CoV-2 Antibodies) Laboratory setting cobas SARS-CoV-2 Test cobas SARS-CoV-2 & Influenza A/B Test NEW: Elecsys SARS-CoV-2 Antigen Test ElecsysAnti-SARS-CoV-2 (N) immunoassay Elecsys Anti-SARS-CoV-2 S Immunoassay Point of Care setting (near patient) SARS-CoV-2 Rapid Antigen Test SARS-CoV-2 Rapid Antigen Test- Nasal cobas Liat SARS-CoV-2 Test** SARS-CoV-2 Rapid Antibody Test**[i] Full specifications of the Roche immunoassay systems, including throughput, can be found on our diagnostics.roche website[ii] European Centre for Disease Prevention and Control.
Your support to NYOOOZ will help us to continue create and publish news for and from smaller cities, which also need equal voice as much as citizens living in bigger cities have through mainstream media organizations.
Stay updated with all the Mumbai Latest News headlines here. For more exclusive & live news updates from all around India, stay connected with NYOOOZ.